{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:04:37Z","timestamp":1790597077628,"version":"4.1.0"},"reference-count":99,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is commonly managed with dietary and lifestyle intervention, and weight loss is often used as a key marker of treatment success. However, changes in body weight alone do not fully describe the effects of lifestyle intervention on liver disease. This narrative review asks when lifestyle-induced changes can support a claim of liver disease modification. Current guidance generally associates sustained weight loss of at least 5% with reduced liver fat, 7\u201310% with reduced liver inflammation, and at least 10% with improvement in fibrosis. The review distinguishes weight loss from biological response, pathological improvement, and long-term clinical benefit. It considers how intervention exposure, biological response, outcome type, and duration of follow-up should be interpreted together. It also addresses differences in patient response, long-term adherence, and the limits of different study designs. Randomized trials, long-term observational studies, and target-trial emulation are considered in relation to what they can establish about causality and long-term benefit. We propose a five-question framework for evaluating lifestyle-induced liver disease modification: Who? What? Through which pathway? What outcome? For how long and with what evidence? Weight loss remains an important treatment target, but it should not be considered synonymous with liver disease modification. Claims of disease modification should reflect the level of evidence available. This framework provides a clearer way to distinguish short-term improvement from meaningful and durable modification of MASLD.<\/jats:p>","DOI":"10.3390\/nu18193202","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:35:59Z","timestamp":1790595359000},"page":"3202","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Weight Loss: Rethinking Dietary and Lifestyle Interventions for Liver Disease Modification in MASLD"],"prefix":"10.3390","volume":"18","author":[{"given":"Abdulrahman","family":"Almujaidel","sequence":"first","affiliation":[{"name":"Department of Public Health, College of Applied Medical Sciences, Qassim University, P.O. Box 6666, Buraydah 51452, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1699-6263","authenticated-orcid":false,"given":"Eman","family":"Marzouk","sequence":"additional","affiliation":[{"name":"Department of Public Health, College of Applied Medical Sciences, Qassim University, P.O. Box 6666, Buraydah 51452, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"103043","DOI":"10.1016\/j.arcmed.2024.103043","article-title":"Global prevalence of nonalcoholic fatty liver disease: An updated review meta-analysis comprising a population of 78 million from 38 countries","volume":"55","author":"Letafatkar","year":"2024","journal-title":"Arch. Med. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.cgh.2024.08.020","article-title":"Global prevalence of advanced liver fibrosis and cirrhosis in the general population: A systematic review and meta-analysis","volume":"23","author":"Zamani","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Friedman","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1756283X13484078","article-title":"Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: A randomized trial","volume":"6","author":"Eckard","year":"2013","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3350\/cmh.2020.0067","article-title":"Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH","volume":"26","author":"Hydes","year":"2020","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: Expert review","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.cgh.2021.01.023","article-title":"Weight loss and weight regain in usual clinical practice: Results from the TARGET-NASH observational cohort","volume":"20","author":"Malespin","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1007\/s10620-014-3380-3","article-title":"Total body weight loss of \u226510% is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis","volume":"60","author":"Glass","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/hep.30782","article-title":"Report on the AASLD\/EASL joint workshop on clinical trial endpoints in NAFLD","volume":"70","author":"Rinella","year":"2019","journal-title":"Hepatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/hep.31121","article-title":"Multicenter validation of association between decline in MRI-PDFF and histologic response in NASH","volume":"72","author":"Loomba","year":"2020","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/hep.30163","article-title":"ADAPT: An algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis","volume":"69","author":"Daniels","year":"2019","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Mak, A.L., Lee, J., van Dijk, A.-M., Vali, Y., Aithal, G.P., Schattenberg, J.M., Anstee, Q.M., Brosnan, M.J., Zafarmand, M.H., and Ramsoekh, D. (2021). Systematic review with meta-analysis: Diagnostic accuracy of Pro-C3 for hepatic fibrosis in patients with non-alcoholic fatty liver disease. Biomedicines, 9.","DOI":"10.3390\/biomedicines9121920"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"C1637","DOI":"10.1152\/ajpcell.00951.2024","article-title":"Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease","volume":"328","author":"Kuchay","year":"2025","journal-title":"Am. J. Physiol.-Cell Physiol."},{"key":"ref_19","first-page":"1","article-title":"Metabolic dysfunction-associated steatotic liver disease-induced changes in the antioxidant system: A review","volume":"99","year":"2025","journal-title":"Arch. Toxicol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1080\/17461391.2019.1571114","article-title":"Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation","volume":"19","author":"Farzanegi","year":"2019","journal-title":"Eur. J. Sport Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/hep.32204","article-title":"Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis","volume":"75","author":"Sanyal","year":"2022","journal-title":"Hepatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.cgh.2022.04.014","article-title":"Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"21","author":"Ng","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jamainternmed.2019.2248","article-title":"Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"179","author":"Koutoukidis","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12937-024-00968-8","article-title":"A comprehensive approach to lifestyle intervention based on a calorie-restricted diet ameliorates liver fat in overweight\/obese patients with NAFLD: A multicenter randomized controlled trial in China","volume":"23","author":"Liu","year":"2024","journal-title":"Nutr. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"154455","DOI":"10.1016\/j.metabol.2020.154455","article-title":"The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"115","author":"Koutoukidis","year":"2021","journal-title":"Metabolism"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/SLA.0000000000000945","article-title":"Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: A 5-year controlled longitudinal study","volume":"260","author":"Caiazzo","year":"2014","journal-title":"Ann. Surg."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-publhealth-032315-021402","article-title":"Mediation analysis: A practitioner\u2019s guide","volume":"37","author":"VanderWeele","year":"2016","journal-title":"Annu. Rev. Public Health"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Yang, C., Yan, P., Deng, J., Li, Y., Jiang, X., and Zhang, B. (2024). Exercise, weight maintenance, and nonalcoholic fatty liver disease risk: A Chinese cohort study. Front. Physiol., 15.","DOI":"10.3389\/fphys.2024.1359476"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.30076","article-title":"Ad libitum Mediterranean and low-fat diets both significantly reduce hepatic steatosis: A randomized controlled trial","volume":"68","author":"Properzi","year":"2018","journal-title":"Hepatology"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Matis, D., Hegyi, P., Teutsch, B., Tornai, T., Er\u0151ss, B., Par, G., and Vancsa, S. (2023). Improved body composition decreases the fat content in non-alcoholic fatty liver disease, a meta-analysis and systematic review of longitudinal studies. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1114836"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.metabol.2016.12.006","article-title":"Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis","volume":"68","author":"Katsagoni","year":"2017","journal-title":"Metabolism"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.14309\/ajg.0000000000002098","article-title":"Exercise training is associated with treatment response in liver fat content by magnetic resonance imaging independent of clinically significant body weight loss in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"118","author":"Stine","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e233513","DOI":"10.1001\/jamanetworkopen.2023.3513","article-title":"Effects of time-restricted eating on nonalcoholic fatty liver disease: The TREATY-FLD randomized clinical trial","volume":"6","author":"Wei","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e13783","DOI":"10.1002\/jcsm.13783","article-title":"Severe Dietary Energy Restriction for Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomised Controlled Trial","volume":"16","author":"Koutoukidis","year":"2025","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jhep.2013.02.012","article-title":"The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease","volume":"59","author":"Ryan","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"E22","DOI":"10.1111\/hepr.12918","article-title":"Comparison of efficacy of low-carbohydrate and low-fat diet education programs in non-alcoholic fatty liver disease: A randomized controlled study","volume":"48","author":"Jang","year":"2018","journal-title":"Hepatol. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.cmet.2018.01.005","article-title":"An integrated understanding of the rapid metabolic benefits of a carbohydrate-restricted diet on hepatic steatosis in humans","volume":"27","author":"Mardinoglu","year":"2018","journal-title":"Cell Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.2337\/db13-1622","article-title":"Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans","volume":"63","author":"Rosqvist","year":"2014","journal-title":"Diabetes"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3945\/ajcn.111.022533","article-title":"Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: A 6-mo randomized intervention study","volume":"95","author":"Maersk","year":"2012","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/hep.25548","article-title":"Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease","volume":"55","author":"Sullivan","year":"2012","journal-title":"Hepatology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1136\/gut.2011.242073","article-title":"Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss","volume":"60","author":"Hallsworth","year":"2011","journal-title":"Gut"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jhep.2015.02.022","article-title":"Effect of aerobic exercise training dose on liver fat and visceral adiposity","volume":"63","author":"Keating","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e00316","DOI":"10.14309\/ctg.0000000000000316","article-title":"Moderate-intensity aerobic vs resistance exercise and dietary modification in patients with nonalcoholic fatty liver disease: A randomized clinical trial","volume":"12","author":"Charatcharoenwitthaya","year":"2021","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/liv.15947","article-title":"Exercise improves surrogate measures of liver histological response in metabolic dysfunction-associated steatotic liver disease","volume":"44","author":"Cuthbertson","year":"2024","journal-title":"Liver Int."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Lee, H.W., Kim, K.J., Jung, K.S., Chon, Y.E., Huh, J.H., Park, K.H., Chung, J.B., Kim, C.O., Han, K.-H., and Park, J.Y. (2017). The relationship between visceral obesity and hepatic steatosis measured by controlled attenuation parameter. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0187066"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/liv.14719","article-title":"Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease","volume":"41","author":"Hsieh","year":"2021","journal-title":"Liver Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e2159","DOI":"10.1097\/MD.0000000000002159","article-title":"Visceral obesity predicts significant fibrosis in patients with nonalcoholic fatty liver disease","volume":"94","author":"Yu","year":"2015","journal-title":"Medicine"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00535-007-2107-z","article-title":"The impact of visceral fat in nonalcoholic fatty liver disease: Cross-sectional and longitudinal studies","volume":"42","author":"Koda","year":"2007","journal-title":"J. Gastroenterol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1111\/liv.13488","article-title":"NAFLD in clinical practice: Can simple blood and anthropometric markers be used to detect change in liver fat measured by 1H-MRS?","volume":"37","author":"Keating","year":"2017","journal-title":"Liver Int."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1136\/gut.2008.151977","article-title":"High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease","volume":"58","author":"Kantartzis","year":"2009","journal-title":"Gut"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1007\/s00125-011-2204-7","article-title":"Reversal of type 2 diabetes: Normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol","volume":"54","author":"Lim","year":"2011","journal-title":"Diabetologia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/hep.30049","article-title":"Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: A 7-year longitudinal study","volume":"68","author":"Kim","year":"2018","journal-title":"Hepatology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/hep.32578","article-title":"Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study","volume":"76","author":"Sinn","year":"2022","journal-title":"Hepatology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hep.22940","article-title":"Independent effects of physical activity in patients with nonalcoholic fatty liver disease","volume":"50","author":"Bauman","year":"2009","journal-title":"Hepatology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/hep.22137","article-title":"Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease","volume":"47","author":"Krasnoff","year":"2008","journal-title":"Hepatology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pcad.2019.01.005","article-title":"Non-alcoholic fatty liver disease: Prevalence and all-cause mortality according to sedentary behaviour and cardiorespiratory fitness. The HUNT Study","volume":"62","author":"Croci","year":"2019","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"101924","DOI":"10.1016\/j.bpg.2024.101924","article-title":"Gut microbiome and metabolic dysfunction-associated steatotic liver disease: Pathogenic role and potential for therapeutics","volume":"72","author":"Rondinella","year":"2024","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41467-022-29968-0","article-title":"A randomized controlled trial for response of microbiome network to exercise and diet intervention in patients with nonalcoholic fatty liver disease","volume":"13","author":"Cheng","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2223339","DOI":"10.1080\/19490976.2023.2223339","article-title":"Gut microbiota in nonalcoholic fatty liver disease: A PREDIMED-Plus trial sub analysis","volume":"15","author":"Vioque","year":"2023","journal-title":"Gut Microbes"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Reshef, N., Gophna, U., Reshef, L., Konikoff, F., Gabay, G., Zornitzki, T., Knobler, H., and Maor, Y. (2024). Prebiotic treatment in patients with nonalcoholic fatty liver disease (NAFLD)\u2014A randomized pilot trial. Nutrients, 16.","DOI":"10.3390\/nu16111571"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2541035","DOI":"10.1080\/19490976.2025.2541035","article-title":"Consecutive fecal microbiota transplantation for metabolic dysfunction-associated steatotic liver disease: A randomized controlled trial","volume":"17","author":"Groenewegen","year":"2025","journal-title":"Gut Microbes"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Dong, T.S., Luu, K., Lagishetty, V., Sedighian, F., Woo, S.-L., Dreskin, B.W., Katzka, W., Chang, C., Zhou, Y., and Arias-Jayo, N. (2021). The intestinal microbiome predicts weight loss on a calorie-restricted diet and is associated with improved hepatic steatosis. Front. Nutr., 8.","DOI":"10.3389\/fnut.2021.718661"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13099-026-00798-5","article-title":"Clinical and microbial correlates of response to lifestyle intervention in pediatric metabolic dysfunction-associated steatotic liver disease","volume":"18","author":"Hahn","year":"2026","journal-title":"Gut Pathog."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"9385","DOI":"10.1038\/s41598-020-66241-0","article-title":"Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools","volume":"10","author":"Lang","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"eabk0855","DOI":"10.1126\/scitranslmed.abk0855","article-title":"Risk assessment with gut microbiome and metabolite markers in NAFLD development","volume":"14","author":"Leung","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"102397","DOI":"10.1016\/j.clinre.2024.102397","article-title":"Clinical improvement effect of regulating gut microbiota on metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis of randomized controlled trials","volume":"48","author":"Wu","year":"2024","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2018.08.011","article-title":"Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease","volume":"69","author":"Wong","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e0224","DOI":"10.1097\/HC9.0000000000000224","article-title":"Behavioral weight-loss interventions for patients with NAFLD: A systematic scoping review","volume":"7","author":"Balakrishnan","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Luo, L., Shao, C., Dong, Z., Zhuo, S., Feng, S., Wang, W., Ye, J., and Zhong, B. (2025). Distinct Markers of Discordant Treatment Response to Lifestyle Intervention in MASLD, Independent of Weight Loss. Biomedicines, 13.","DOI":"10.3390\/biomedicines13092161"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1016\/j.cgh.2022.08.036","article-title":"Clinical utility of combined MRI-PDFF and ALT response in predicting histologic response in nonalcoholic fatty liver disease","volume":"21","author":"Huang","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Sangprasert, S., Kwancharoen, R., Ruamtawee, W., and Sethasine, S. (2025). Factors influencing effective decrease of controlled attenuation parameters in metabolic-associated steatotic liver disease: A multilevel linear regression analysis at Vajira Hospital. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0336294"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/apt.15063","article-title":"Impact of a structured lifestyle programme on patients with metabolic syndrome complicated by non-alcoholic fatty liver disease","volume":"49","author":"Konerman","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2013.04.013","article-title":"Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial","volume":"59","author":"Wong","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e49839","DOI":"10.2196\/49839","article-title":"Mobile app\u2013based lifestyle coaching intervention for patients with nonalcoholic fatty liver disease: Randomized controlled trial","volume":"26","author":"Kwon","year":"2024","journal-title":"J. Med. Internet Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/liv.14818","article-title":"Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: A randomized trial","volume":"41","author":"Cantero","year":"2021","journal-title":"Liver Int."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e001771","DOI":"10.1136\/bmjgast-2025-001771","article-title":"Feasibility of a digital lifestyle intervention (VITALISE) to support weight loss in patients with MASLD in routine secondary care","volume":"12","author":"Avery","year":"2025","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","article-title":"Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis","volume":"19","author":"Stine","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Au, T.Y., Darekar, A., Wong, V.W.-S., Foucquier, J., Fournier, C., Amin, N.B., and Anstee, Q.M. (2026). Reproducibility of Biomarkers in MASLD: A Benchmark for Clinically Meaningful Change in Serially Measured Non-Invasive Tests. J. Hepatol., online ahead of print.","DOI":"10.1016\/j.jhep.2026.07.029"},{"key":"ref_88","unstructured":"FDA (2026, August 28). Review and Approval Correspondence for Resmetirom (REZDIFFRA), Available online: https:\/\/www.fda.gov\/drugs\/development-resources\/table-surrogate-endpoints-were-basis-drug-approval-or-licensure."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: A framework for causal inference from observational data","volume":"328","author":"Wang","year":"2022","journal-title":"JAMA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1136\/gutjnl-2020-323106","article-title":"Effect of green-Mediterranean diet on intrahepatic fat: The DIRECT PLUS randomised controlled trial","volume":"70","author":"Rinott","year":"2021","journal-title":"Gut"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e2325907","DOI":"10.1001\/jamanetworkopen.2023.25907","article-title":"Reducing bias in estimates of per protocol treatment effects: A secondary analysis of a randomized clinical trial","volume":"6","author":"Cole","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/aje\/kwad141","article-title":"Estimating the effect of a treatment when there is nonadherence in a trial","volume":"192","author":"Richardson","year":"2023","journal-title":"Am. J. Epidemiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41598-019-57369-9","article-title":"Effect of weight change and lifestyle modifications on the development or remission of nonalcoholic fatty liver disease: Sex-specific analysis","volume":"10","author":"Yoshioka","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.14309\/ajg.0000000000002222","article-title":"Significant dose-response association of physical activity and diet quality with mortality in adults with suspected NAFLD in a population study","volume":"118","author":"Vuppalanchi","year":"2023","journal-title":"Off. J. Am. Coll. Gastroenterol.|ACG"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/00491241211055769","article-title":"The gap-closing estimand: A causal approach to study interventions that close disparities across social categories","volume":"53","author":"Lundberg","year":"2024","journal-title":"Sociol. Methods Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jama.2025.13350","article-title":"Transparent reporting of observational studies emulating a target trial\u2014The TARGET statement","volume":"334","author":"Cashin","year":"2025","journal-title":"JAMA"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Robins","year":"2016","journal-title":"Am. J. Epidemiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/j.cgh.2025.12.001","article-title":"Expert Delphi Consensus on Surrogate Endpoints for Treatment Assessment in Metabolic Dysfunction-Associated Steatohepatitis","volume":"24","author":"Sanyal","year":"2026","journal-title":"Clin. Gastroenterol. Hepatol."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/18\/19\/3202\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:53:32Z","timestamp":1790596412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/18\/19\/3202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":99,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["nu18193202"],"URL":"https:\/\/doi.org\/10.3390\/nu18193202","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]}}}